Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 3

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
,2025202420252024Products and services revenue$145,157 $152,990 $282,980 $293,995 License and royalty revenue27,751 114 44,811 115 Revenue172,908 153,104 327,791 294,110 Cost of products and services revenue47,824 48,884 97,262 96,976 Gross profit125,084 104,220 230,529 197,134 Operating expenses:Research and development61,224 62,918 125,469 131,556 Selling, general and administrative74,434 83,039 164,162 168,813 Gain on settlement(40,700)— (49,900)— Total operating expenses94,958 145,957 239,731 300,369 Income (loss) from operations30,126 (41,737)(9,202)(103,235)Other income (expense):Interest income4,271 4,715 7,957 9,451 Interest expense(3)(1)(3)(2)Other income (expense), net2,603 (56)4,739 (1,096)Total other income6,871 4,658 12,693 8,353 Income (loss) before provision for income taxes36,997 (37,079)3,491 (94,882)Provision for income taxes2,459 818 3,311 2,964 Net income (loss)$34,538 $(37,897)$180 $(97,846)Net income (loss) per share, basic$0.28 $(0.32)$0.00 $(0.82)Net income (loss) per share, diluted$0.28 $(0.32)$0.00 $(0.82)Weighted-average shares used to compute net income (loss) per share, basic123,755,409 120,066,972 123,183,924 119,461,485 Weighted-average shares used to compute net income (loss) per share, diluted124,509,720 120,066,972 124,258,150 119,461,485 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

10x Genomics